Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NQ0V
|
|||
| Former ID |
DNCL003699
|
|||
| Drug Name |
BT-061
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Phase 2 | [1], [2] | |
| Psoriasis vulgaris [ICD-11: EA90] | Phase 2 | [1], [2] | ||
| Company |
Biotest
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01072383) Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis. U.S. National Institutes of Health. | |||
| REF 2 | A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015 Apr;93(4):396-405. | |||
| REF 3 | Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.